RxDoctor Payments Data

Rene Duregger, MD

Child & Adolescent Psychiatry · Mason City, IANPI 1245436765

Payments from drug & device makers

What this record shows

Almost everything reported here is food and beverage — 100.0% of the total across 64 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 18 manufacturers, the largest accounting for just 17.0% — the pattern of someone who eats at a lot of different presentations. Reporting peaked in 2024 at $356 and has fallen 95.6% since, to $16 in 2025.

$1,065in general payments, 2019–2025

Across 64 payments — averaging $16.64 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Otsuka America Pharmaceutical, Inc.$181
  • AbbVie$159
  • Johnson & Johnson$102
  • Lundbeck LLC$69
  • ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)$64
  • Axsome Therapeutics, Inc.$57
  • plus $433 from 12 others

What the payments were for

  • Food & beverage$1,065100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$1,065 in reported general payments places this provider in the 65th percentile of 20 child & adolescent psychiatry providers in Iowa.

See all child & adolescent psychiatry providers in Iowa

Medicare billing

Part B allowed, 2024
$33,162
Medicare patients
104
Services billed
680

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
VraylarCariprazine Hcl23$26,464
TrintellixVortioxetine Hydrobromide11$5,131
Aripiprazole17$1,153
Duloxetine Hcl105$984
Lurasidone Hcl21$843
Bupropion XlBupropion Hcl50$648
Quetiapine Fumarate52$492
Lamotrigine48$451
Hydroxyzine Hcl15$335
Prazosin Hcl29$279
Buspirone Hcl45$278
Fluoxetine Hcl45$273
Venlafaxine Hcl ErVenlafaxine Hcl32$261
Trazodone Hcl65$241
Benztropine Mesylate25$238

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AbbVieVraylar$159$26,46423 claims
Takeda Pharmaceuticals U.S.A., Inc.Trintellix$27$5,13111 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 65th percentile of 20 child & adolescent psychiatry providers in Iowa.

Other child & adolescent psychiatry in Mason City

See the full list for Iowa

Where these figures come from

Is this you, or does something look wrong? →